National Bank of Canada
LENZ

National Bank of Canada’s LENZ Therapeutics LENZ Stock Holding History

National Bank of Canada’s Portfolio LENZ Stock Details LENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$51.1K Buy
5,600
+750
+15% +$10.5K ﹤0.01% 1975
2025
Q4 		$77.3K Buy
4,850
+4,508
+1,318% +$131K ﹤0.01% 1845
2025
Q3 		$15.9K Buy
+342
New +$12.6K ﹤0.01% 2211

Other funds holding LENZ

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
AWG
Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
7IH
72 Investment Holdings Stamford, Connecticut $49.6M AUM 684.72% 1-Year Est. Return

National Bank of Canada's LENZ Position: Q1 2026 in Review

National Bank of Canada increased its LENZ Therapeutics (LENZ) stake by 15% in Q1 2026, buying an estimated $10.5K and bringing the position to 5,600 shares worth $51.1K. The position accounts for ﹤0.01% of the portfolio, ranked #1975.

National Bank of Canada first reported a position in LENZ in Q3 2025 and has held it in 3 quarters since. The position peaked at $77.3K in Q4 2025. 145 funds tracked by Wall St. Rank hold LENZ as of Q1 2026.

  • National Bank of Canada held 5,600 shares of LENZ Therapeutics worth $51.1K as of Q1 2026.
  • National Bank of Canada bought 750 LENZ Therapeutics shares in Q1 2026, an estimated $10.5K.
  • LENZ Therapeutics made up ﹤0.01% of National Bank of Canada's portfolio in Q1 2026, its #1975 holding.
  • National Bank of Canada first reported a position in LENZ Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • National Bank of Canada's LENZ Therapeutics position peaked at $77.3K in Q4 2025.
  • 145 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q1 2026.

Based on National Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.